Product image of Milrinon Stragen (Milrinone) supplied by GNH India

Milrinon Stragen

Active Ingredient:
Milrinone
Origin:
EU

Milrinon Stragen (Milrinone)

Milrinone, the active ingredient in Milrinon Stragen, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is employed in the management of acute decompensated heart failure and cardiogenic shock, providing inotropic support to improve cardiac output in hospitalized patients.

GNH India supplies Milrinon Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care units worldwide, with distribution networks across Europe, Asia, Africa and the Americas and adhering to stringent quality standards throughout the supply chain.

Manufacturer / TM Owner

Stragen Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Milrinon Stragen is a phosphodiesterase‑3 inhibitor used in critical cardiac conditions where enhanced contractility is required.
  • Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion.
  • Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion.
  • Low cardiac output syndrome after cardiac surgery: enhances myocardial contractility to aid hemodynamic stabilization.

How It Works

  • Milrinone selectively inhibits phosphodiesterase‑3 enzymes, leading to an accumulation of intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP increases calcium influx in cardiac myocytes, which enhances myocardial contractility, and also causes vascular smooth‑muscle relaxation, resulting in vasodilation and reduced after‑load.

Side Effects

Milrinon Stragen may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

  • Hypotension: drop in systemic blood pressure.
  • Tachyarrhythmias: accelerated heart rhythms such as atrial fibrillation.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Flushing: transient warmth and redness of the skin.
  • Thrombocytopenia: mild reduction in platelet count.

Serious or Rare Side Effects

  • Severe hypotension: profound blood pressure fall requiring intervention.
  • Ventricular arrhythmias: life‑threatening heart rhythm disturbances.
  • Myocardial ischemia: reduced blood flow to heart muscle.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Hemorrhage: bleeding due to platelet effects.
  • Death: rare but reported in severe cases.

Precautions & Warnings

  • Milrinon Stragen requires careful monitoring and specific precautions before and during administration.
  • Monitor blood pressure: watch for hypotension and adjust infusion rate.
  • Observe cardiac rhythm: continuous ECG monitoring for arrhythmias.
  • Assess renal function: dose may need adjustment in renal impairment.
  • Use cautiously in ischemic heart disease: risk of myocardial ischemia.
  • Avoid in known hypersensitivity: discontinue if allergic reaction occurs.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Milrinon Stragen can interact with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

  • Concurrent potent vasodilators (e.g., nitroglycerin): may cause severe hypotension.
  • Other inotropes (e.g., dopamine, dobutamine): risk of excessive cardiac stimulation.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase milrinone plasma levels.
  • Anti‑arrhythmic agents (e.g., amiodarone, quinidine): heightened arrhythmia risk.
  • Monoamine oxidase inhibitors: unpredictable cardiovascular effects.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt desired inotropic response.
  • Diuretics: combined effect on blood pressure and electrolytes.
  • ACE inhibitors or ARBs: additive hypotensive effect.
  • Calcium channel blockers: possible synergistic vasodilation.
  • Anticoagulants: monitor for bleeding if thrombocytopenia develops.

Frequently Asked Questions

Milrinon Stragen is an intravenous formulation of milrinone used primarily in hospital settings to treat acute decompensated heart failure and cardiogenic shock. It provides inotropic support that improves cardiac contractility and helps stabilize hemodynamics in critically ill patients.

Milrinone works by selectively inhibiting the phosphodiesterase‑3 enzyme, which raises intracellular cyclic AMP levels. The increase in cAMP enhances calcium entry into cardiac cells, boosting contractile force, while also causing vasodilation of peripheral vessels, thereby reducing cardiac after‑load.

The dosing regimen for Milrinon Stragen is determined by the treating physician based on the patient’s clinical status, weight, renal function and response to therapy. Physicians typically start with a loading dose followed by a continuous infusion, but exact rates are individualized.

Safety data for milrinone during pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To order Milrinon Stragen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Milrinone and dobutamine are both inotropic agents, but milrinone is a phosphodiesterase‑3 inhibitor while dobutamine is a β‑adrenergic agonist. Milrinone has a longer half‑life and provides both inotropic and vasodilatory effects, which can be advantageous in patients with high systemic vascular resistance, whereas dobutamine primarily increases contractility with less vasodilation.

Milrinon Stragen must be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and do not freeze or shake vigorously. Before use, allow the product to reach room temperature if required by the administration protocol.

Milrinon Stragen is administered intravenously, usually as an initial loading dose followed by a continuous infusion. The infusion is delivered through a calibrated infusion pump, and the rate is adjusted according to the patient’s hemodynamic response and monitoring parameters.

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischemia, and rare cases of anaphylactic reactions. Continuous blood pressure and ECG monitoring are essential to detect these events promptly.

Milrinon Stragen is contraindicated in patients with known hypersensitivity to milrinone or any excipients, in those with severe aortic or pulmonic valve stenosis, and in patients who have experienced life‑threatening ventricular arrhythmias related to milrinone therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Milrinone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT